

Amendments to the Specification:

Please amend the paragraph on page 3, lines 17, through page 11, line 30, beginning, "Specifically, the present invention provides:..." as follows:

--Specifically, the present invention provides:

<1> a pharmaceutical agent comprising a dipeptidyl peptidase IV inhibitor and a biguanide agent in combination;

<2> the pharmaceutical agent according to <1>, which enhances the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2);

<3> a pharmaceutical agent that enhances the effects of active circulating GLP-2;


<4> a pharmaceutical agent comprising a dipeptidyl peptidase IV inhibitor and the pharmaceutical agent according to <3> in combination;

<5> the pharmaceutical agent according to <1> or <4>, wherein the dipeptidyl peptidase IV inhibitor is any one compound selected from:

(S)-1-((3-hydroxy-1-adamantyl)amino)acetyl-2-cyanopyrrolidine; (S)-1-(2-((5-cyanopyridin-2-yl)amino)ethyl-aminoacetyl)-2-cyanopyrrolidine; isoleucine thiazolidide; isoleucine pyrrolidine; and valine pyrrolidine;

or a salt or hydrate thereof;

<6> the pharmaceutical agent according to <1> or <4>, wherein the dipeptidyl peptidase IV inhibitor is a compound represented by the following formula, or a salt or hydrate thereof,



(wherein,

T¹ represents a monocyclic or bicyclic 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, that may have one or more substituents;

X represents a C₁₋₆ alkyl group which may have one or more substituents, a C₂₋₆ alkenyl group which may have one or more substituents, a C₂₋₆ alkynyl group which may have one or more substituents, a C₆₋₁₀ aryl group which may have one or more substituents, a 5 to 10-membered heteroaryl group which may have one or more substituents, a C₆₋₁₀ aryl C₁₋₆ alkyl group which may have one or more substituents, or a 5 to 10-membered heteroaryl C₁₋₆ alkyl group which may have one or more substituents;

Z¹ and Z² each independently represent a nitrogen atom or a group represented by the formula -CR²=;

R¹ and R² each independently represent a group according to the formula -A⁰-A¹-A²

(wherein A⁰ represents a single bond or a C₁₋₆ alkylene group, which may have 1 to 3 substituents selected from group B consisting of the substituents described below;

A¹ represents a single bond, an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a group represented by the formula -O-CO-, a group represented by the formula -CO-O-, a group represented by the formula -NR^A-, a group represented by the formula -CO-NR^A-, a group represented by the formula -NR^A-CO-, a group represented by the formula -SO₂-NR^A-, or a group represented by the formula -NR^A-SO₂-;

A² and R^A each independently represent a hydrogen atom, a halogen atom, a cyano group, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, C₆₋₁₀ aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a 5 to 10-membered heteroaryl C₁₋₆ alkyl group, a C₆₋₁₀ aryl C₁₋₆ alkyl group, or a C₂₋₇ alkylcarbonyl group;

however, A² and R^A each independently may have 1 to 3 substituents selected from the substituent group B described below:

when Z² is a group represented by the formula -CR²=, R¹, and R² may in combination form a 5 to 7-membered ring;

except in cases where: [1] R¹ is a hydrogen atom; Z¹ is a nitrogen atom; and Z² is -CH=; and [2] Z¹ is a nitrogen atom; and Z² is -C(OH)=;

<Substituent group B>

Substituent group B represents the group consisting of: a hydroxyl group, a mercapto group, a cyano group, a nitro group, a halogen atom, a trifluoromethyl group, a C₁₋₆ alkyl group which may have one or more substituents, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a group represented by the formula -SO₂-NR^{B1}-R^{B2}, a group represented by the formula -NR^{B1}-CO-R^{B2}, a group represented by the formula -NR^{B1}-R^{B2} (where R^{B1} and R^{B2} each independently represent a hydrogen atom or a C₁₋₆ alkyl group), a group represented by the formula -CO-R^{B3} (where R^{B3} represents a 4 to 8-membered heterocyclic group), a group represented by the formula -CO-R^{B4}-R^{B5} and a group represented by the formula -CH₂-CO-R^{B4}-R^{B5} (where R^{B4} represents a single bond, an oxygen atom, or a group represented by the formula -NR^{B6}-; R^{B5} and R^{B6} each independently represent a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic C₁₋₆ alkyl group, a C₆₋₁₀ aryl C₁₋₆ alkyl group, or a 5 to 10-membered heteroaryl C₁₋₆ alkyl group));

<7> the pharmaceutical agent according to <6>, wherein T¹ is a piperazin-1-yl group or a 3-amino-piperidin-1-yl group;

<8> the pharmaceutical agent according to <6>, wherein T¹ is a piperazin-1-yl group;

<9> the pharmaceutical agent according to any one of <6> to <8>, wherein X is a 3-methyl-2-buten-1-yl group, a 2-butynyl group, a benzyl group, or a 2-chlorophenyl group;

<10> the pharmaceutical agent according to any one of <6> to <8>, wherein X is a 3-methyl-2-buten-1-yl group or a 2-butyn-1-yl group;

<11> the pharmaceutical agent according to any one of <6> to <8>, wherein X is a 2-butyn-1-yl group;

<12> the pharmaceutical agent according to any one of <6> to <11>, wherein,

Z^1 is a nitrogen atom; and

Z^2 is a group represented by the formula $[-\text{CR}_2=]$ $-\text{CR}^2=$

(where R^2 is as defined in <6>);

<13> the pharmaceutical agent according to any one of <6> to <11>, wherein,

Z^2 is a nitrogen atom; and


Z^1 is a group represented by the formula $[-\text{CR}_2=]$ $-\text{CR}^2=$

(where R^2 is as defined in <6>);

<14> the pharmaceutical agent according to any one of <6> to <13>, wherein R^1 is either a methyl group, a cyanobenzyl group, a fluorocyanobenzyl group, a phenethyl group, a 2-methoxyethyl group, or a 4-methoxycarbonylpridin-2-yl group;

<15> the pharmaceutical agent according to any one of <6> to <13>, wherein R^1 is a methyl group, or a 2-cyanobenzyl group;

<16> the pharmaceutical agent according to any one of <6> to <15>, wherein R^2 is either a hydrogen atom, a cyano group, a methoxy group, a carbamoylphenyloxy group, or a group represented by the formula:



(where,

A^{27} represents an oxygen atom, a sulfur atom, or $-\text{NH}-$;

A^{28} and A^{29} each independently represent a hydrogen atom or a C_{1-6} alkyl group);


<17> the pharmaceutical agent according to any one of <6> to <15>, wherein R^2 is a hydrogen atom, a cyano group, or a 2-carbamoylphenyloxy group;

<18> the pharmaceutical agent according to <6>, wherein the compound represented by formula (I) is any one compound selected from:

- (1) 7-(2-butynyl)-2-cyano-1-methyl-8-(piperazin-1-yl)-1,7-dihdropurin-6-one;
- (2) 3-(2-butynyl)-5-methyl-2-(piperazin-1-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one;
- (3) 2-(3-aminopiperidin-1-yl)-3-(2-butynyl)-5-methyl-3,5-dihydroimidazo[4,5-d]pyridazin-4-one;
- (4) 2-[7-(2-butynyl)-1-methyl-6-oxo-8-(piperazin-1-yl)-6,7-dihydro-1H-purin-2-yloxy]benzamide;
- (5) 7-(2-butynyl)-1-(2-cyanobenzyl)-6-oxo-8-(piperazin-1-yl)-6,7-dihydro-1H-purine-2-carbonitrile; and
- (6) 2-[3-(2-butynyl)-4-oxo-2-(piperazin-1-yl)-3,4-dihydroimidazo[4,5-d] pyridazin-5-ylmethyl] benzonitrile;

or a salt or hydrate thereof;

<19> the pharmaceutical agent according to <1> or <4>, wherein the dipeptidyl peptidase IV inhibitor is a compound represented by the following formula, or a salt or hydrate thereof,




(wherein T^1 , X , R^1 , and R^2 are as defined in <6>);

<20> the pharmaceutical agent according to <19>, wherein T^1 is a piperazin-1-yl group;

<21> the pharmaceutical agent according to <19> or <20>, wherein X is a 2-butynyl group or a 2-chlorophenyl group;


<22> the pharmaceutical agent according to <19> or <20>, wherein X is a 2-butynyl group;

<23> the pharmaceutical agent according to any one of <19> to <22>, wherein R¹ is a hydrogen atom, a methyl group, a 2-propynyl group, a 2-butynyl group, a cyanomethyl group, a phenethyl group, a phenoxyethyl group, or a group represented by the formula:



(where R³ represents a hydroxyl group, a C₁₋₆ alkoxy group, or a phenyl group);


<24> the pharmaceutical agent according to any one of <19> to <23>, wherein R² is a hydrogen atom, a C₁₋₆ alkyl group, an ethoxyethyl group, a tetrahydrofurylmethyl group, or a group represented by the formula:



(where,

R⁴ and R⁵ are identical to or different from each other, and independently represent a hydrogen atom, a methyl group, or a phenyl group; and

R⁶ represents a hydroxyl group, a C₁₋₆ alkoxy group, or a phenyl group), or a group represented by the formula:



<25> the pharmaceutical agent according to <19>, wherein the compound represented by formula (II) is any one compound selected from:

- (1) 7-(2-butynyl)-1,3-dimethyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (2) 7-(2-butynyl)-3-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (3) methyl [7-(2-butynyl)-3-methyl-2,6-dioxo-8-(piperazin-1-yl)-2,3,6,7-tetrahydropurin-1-yl] acetate;
- (4) 7-(2-butynyl)-3-methyl-8-(piperazin-1-yl)-1-(2-propynyl)-3,7-dihydropurine-2,6-dione;

- (5) 1,7-bis(2-butynyl)-3-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (6) [7-(2-butynyl)-3-methyl-2,6-dioxo-8-(piperazin-1-yl)-2,3,6,7-tetrahydropurin-1-yl] acetonitrile;
- (7) 7-(2-butynyl)-3-methyl-1-[(2-oxo-2-phenyl)ethyl]-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (8) 7-(2-butynyl)-3-ethyl-1-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (9) methyl [7-(2-butynyl)-1-methyl-2,6-dioxo-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl] acetate;
- (10) 7-(2-butynyl)-3-(2-tetrahydrofuranyl)methyl-1-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (11) methyl [7-(2-butynyl)-1-methyl-2,6-dioxo-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl]phenylacetate;
- (12) 7-(2-butynyl)-3-propyl-1-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (13) 7-(2-butynyl)-3-(2-oxo-2-phenethyl)-1-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (14) ethyl 2-[7-(2-butynyl)-1-methyl-2,6-dioxo-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl] propionate;
- (15) 7-(2-butynyl)-3-(2-ethoxyethyl)-1-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (16) 7-(2-butynyl)-3-isopropyl-1-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (17) 7-(2-butynyl)-3-(3,3-dimethyl-2-oxobutyl)-1-methyl-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (18) 7-(2-butynyl)-1-methyl-3-(2-oxopyrrolidin-3-yl)-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (19) 7-(2-butynyl)-3-(2-ethoxyethyl)-1-(2-oxo-2-phenylethyl)-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (20) methyl [7-(2-butynyl)-2,6-dioxo-1-(2-oxo-2-phenylethyl)-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl] acetate;

- (21) ethyl [7-(2-butynyl)-2,6-dioxo-1-(2-phenethyl)-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl] acetate;
- (22) [7-(2-butynyl)-2,6-dioxo-1-(2-phenethyl)-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl] acetate;
- (23) 7-(2-butynyl)-3-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-1-(2-phenethyl)-8-(piperazin-1-yl)-3,7-dihydropurine-2,6-dione;
- (24) 2-[7-(2-butynyl)-2,6-dioxo-1-(2-phenethyl)-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl]-N-methylacetamide;
- (25) 2-[7-(2-butynyl)-2,6-dioxo-1-(2-phenethyl)-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl]-N-cyclopropyl acetamide;
- (26) 2-[7-(2-butynyl)-2,6-dioxo-1-(2-phenethyl)-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl]-N-phenylacetamide; and
- (27) 2-[7-(2-butynyl)-2,6-dioxo-1-(2-phenethyl)-8-(piperazin-1-yl)-1,2,6,7-tetrahydropurin-3-yl]-N-(2-propynyl) acetamide;

or a salt or hydrate thereof;

<26> the pharmaceutical agent according to <1>, wherein the biguanide agent is metformin;

<27> the pharmaceutical agent according to <1> or <2>, which is a preventive or therapeutic agent for a disease which is associated with active circulating GLP-1 and/or active circulating GLP-2;

<28> the pharmaceutical agent according to <27>, wherein the disease is at least any one selected from the group consisting of: diabetes, obesity, hyperlipidemia, and gastrointestinal diseases;

<29> the pharmaceutical agent according to <3> or <4>, which is a preventive or therapeutic agent for a disease which is associated with active circulating GLP-2;

<30> the pharmaceutical agent according to <29>, wherein the disease is a gastrointestinal disease;

<31> a method for preventing or treating a disease which is associated with active circulating GLP-1 and/or active circulating GLP-2, which comprises administering the pharmaceutical agent according to <1> or <2> at an effective amount;

<32> the use of the pharmaceutical agent according to <1> or <2> for producing a preventive or therapeutic agent for a disease which is associated with active circulating GLP-1 and/or active circulating GLP-2;

<33> a method for preventing or treating a disease which is associated with active circulating GLP-2 , which comprises administering the pharmaceutical agent according to <3> or <4> at an effective amount;

<34> the use of the pharmaceutical agent according to <3> or <4> for producing a preventive or therapeutic agent for a disease which is associated with active circulating GLP-2;

<35> a method for enhancing the effects of active circulating GLP-1 and/or active circulating GLP-2, which comprises using the pharmaceutical agent according to <1> or <2>; and

<36> a method for enhancing the effects of active circulating GLP-2, which comprises using the pharmaceutical agent according to <3> or <4>.--

Please amend the heading on page 88, lines 24-25 as follows:

--[[(d) [7-(2-Chlorophenyl)-1-methyl-2,6-dioxo-1,2,6,7-tetrahydropurin-3-yl]methyl 2,2-dimethylpropionate]] (d) [7-(2-Chlorophenyl)-1-methyl-2,6-dioxo-1,2,6,7-tetrahydropurin-3-yl]methyl 2,2-dimethylpropionate --.

Please amend the paragraph on page 107, lines 5-11, beginning, "0.235 of trimethyl oxonium tetrafluoroborate was added to a 20-ml dichloromethane...", as follows:

--0.235 0.235 g of trimethyl oxonium tetrafluoroborate was added to a 20-ml dichloromethane solution of 0.58 g of t-butyl 4-[1-(2-butynyl)-5-ethoxycarbonyl-4-thiocarbamoyl-1H-imidazol-2-yl]piperazine-1-carboxylate, and the mixture was stirred at room temperature for 18 hours. 50 ml of dichloromethane was added to the solution, and the mixture was washed with 20

ml of a saturated sodium bicarbonate solution. The mixture was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 0.55 g of the title compound.--

Please amend the heading on page 124, lines 6-8 as follows:

--[(f) t-Butyl [1-[7-(2-butynyl)-2-cyano-1-(2-cyanobenzyl)-6-oxo-6,7-dihydro-1-purin-8-yl]piperidin-3-yl]carbamate]] (f) t-Butyl [1-[7-(2-butynyl)-2-cyano-1-(2-cyanobenzyl)-6-oxo-6,7-dihydro-1H-purin-8-yl]piperidin-3-yl]carbamate--.

Please amend the heading for the compound found on page 175, second column, second compound from the top as follows:

--Example 1 (g)-2 Example 1 (g)-1--.